Skip to content
Medical Health Aged Care, Seniors Interest

National audit reveals key strengths and opportunities for medication oversight in Australian aged care

Monash University 2 mins read

A new national audit led by Monash University has shed light on how medication use is governed in Australian residential aged care, revealing wide variation in the structure and function of Medication Advisory Committees (MACs) across the country.

MACs are central to promoting medication safety in residential aged care, with their presence identified as a key intervention to managing the issue of polypharmacy – the use of nine or more medications simultaneously. 

A MAC is a ‘multidisciplinary committee that provides overarching governance of medication management within residential care homes’. The Australian Government Department of Health, Disability and Ageing recommends that all residential care homes have access to a MAC to support safe use of medications and, ultimately, mitigate risks associated with inappropriate prescribing.

Researchers from the Centre for Medicine Use and Safety (CMUS), within the Monash Institute of Pharmaceutical Sciences (MIPS), led the national audit to examine how MACs function across their four recommended operational domains; policy development, risk management, education, and quality improvement.

The audit, adapted from the Department of Health and Aged Care’s MAC Audit Tool, involved 120 MACs overseeing 642 residential care homes – almost a quarter of all Australian residential care homes. 

The findings show that MACs are actively involved in policy and risk oversight – with 59 and 53 per cent respectively performing all recommended functions – with further opportunities for capacity building and long-term improvement. Overall, 41 per cent fulfilled all educational roles, and 28 per cent were fully engaged in quality improvement initiatives.

The study’s lead author, CMUS research fellow Dr Amanda Cross, said “this audit highlights both the strengths and the areas needing targeted support in how we manage and govern medication safety in aged care. MACs have the potential to lead transformational change in this sector – if adequately supported and resourced.”

With the new strengthened Aged Care Quality Standards due to commence on 1 July 2025, Dr Cross says “MACs are well positioned to support implementation and monitoring of Quality Standard 5 to ensure delivery of safe and quality clinical care to the almost 200,000 older Australians who access residential care.”

The study forms part of a larger program of work funded by the Medical Research Future Fund. Professor Simon Bell, project lead of the Maximising Embedded Pharmacists in aGed cAre Medication Advisory Committees (MEGA-MAC) project, said that “the national quality improvement collaborative implemented as part of the MEGA-MAC project utilises a real-time clinical network designed to deliver, monitor and evaluate quality improvement initiatives.”

Research

The audit, titled National audit of the structure and function of Australian residential care medication advisory committees has been published in the Australasian Journal of Ageing. 

DOI: http://dx.doi.org/10.1111/ajag.70048 

 


Contact details:

Kate Carthew

0447 822 659

[email protected] 

Media

More from this category

  • CharitiesAidWelfare, Medical Health Aged Care
  • 17/12/2025
  • 06:00
Leukaemia Foundation

Leukaemia Foundation welcomes South Australian Government commitment to establish dedicated CAR T therapy service

The Leukaemia Foundation has welcomed the announcement by theMalinauskas Labor Government that South Australia is establishing a dedicated CAR T-cell therapy service as a line of treatment for people living with blood cancer – marking a major advancement in cancer care in the State. The new service, expected to commence by mid-2026, will significantly improve access to this highly specialised, life-saving treatment and reduce the need for South Australians to travel interstate for care. Leukaemia Foundation Chief Executive Officer Chris Tanti said the announcement represented a huge win for blood cancer patients and their families. “This is a landmark step…

  • Medical Health Aged Care
  • 17/12/2025
  • 01:10
WW International Inc.

Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that lastNEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated experience bringing together comprehensive support for members on GLP-1 medications, personalised nutrition, behavioural support, coaching, and community within a redesigned app and digital platform. Built for a new era of weight management and long-term health, the new integrated offering delivers coordinated, evidence-based…

  • Medical Health Aged Care
  • 16/12/2025
  • 12:11
Esco Aster Pte. Ltd.

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

SINGAPORE–BUSINESS WIRE– Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.